Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Kater AP"'
Autor:
Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P, CLL, ERIC European Res Initiative
Publikováno v:
Leukemia
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223b87a88cadbba63e43e546bd4fa680